Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations revealed findings from the preclinical evaluation of 1H5, a novel monoclonal antibody (mAb) candidate that inhibits the NOTCH signaling pathway and is being developed for the treatment of high-grade gliomas (HGGs).
A U.K. study has uncovered distinctive genetic drivers of type 2 diabetes in South Asians that lead to faster development of complications, the need for earlier insulin replacement therapy and a weaker response to some widely prescribed drugs. That points to the need to refine care pathways. But in addition, the research provides a potent illustration of how the under-representation in genomics databases of people who are not of white European origin can skew results and be a source of discrimination.
Leal Therapeutics Inc. has divulged mitochondrial glutaminase kidney isoform (GLS, GLS1) inhibitors reported to be useful for the treatment of neurological and psychiatric disorders.
Nain Biotech (Hangzhou) Co. Ltd. has identified tetrahydrocarbazole derivatives reported to be useful for the treatment of cancer and viral infections.
Foghorn Therapeutics Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising ubiquitin ligase binding moieties covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety reported to be useful for the treatment of cancer and viral infection.
There is increasing interest in developing precision immunotherapies that target tumors but with minimal impact on healthy tissues. IL-12 is a potent immunostimulatory cytokine that has shown effective antitumoral activity in the preclinical setting, but its systemic delivery may be accompanied by off-target effects.
Ferroptosis is a programmed cell death mechanism driven specifically by lipid peroxidation. Previous research found that ferroptosis is linked to the onset and progression of cardiovascular diseases, particularly those closely associated with vascular endothelial cell (VEC) injury.
Researchers from presented preclinical data for AVX-70371, a novel therapeutic vaccine being developed for the treatment of chronic hepatitis B virus (HBV) infection.
RSS
